Cardiovascular dysfunctions and sympathovagal imbalance in hypertension and prehypertension: Physiological perspectives

Future Cardiology

Volumn 9, Issue 1, 2013, Pages 53-69

  Pal, Gopal Krushna ^a   Pal, Pravati ^a   Nanda, Nivedita ^b   Amudharaj, Dharmalingam ^a   Adithan, Chandrasekaran ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b PONDICHERRY INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

cardiac dysfunction; hypertension; LF:HF ratio; prehypertension sympathovagal imbalance; vagal withdrawal

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST;

AEROBIC EXERCISE; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR DYSFUNCTION; EMOTIONAL STRESS; HOMEOSTASIS; HUMAN; HYPERTENSION; JOB STRESS; LIFESTYLE; NONHUMAN; OXIDATIVE STRESS; PARASYMPATHETIC FUNCTION; PATHOPHYSIOLOGY; PREHYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SYMPATHETIC FUNCTION; SYMPATHOVAGAL IMBALANCE; VASCULAR ENDOTHELIUM;

HOMEOSTASIS; HUMANS; HYPERTENSION; LIFE STYLE; PREHYPERTENSION; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM; VAGUS NERVE;

EID: 84871565394     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.12.80     Document Type: Review

References (217)

1. Grassi G, Bombelli M, Brambilla G, Trevano FQ, Dell'oro R, Mancia G. Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications. Curr. Hypertens. Rep. 14(4), 333-338 (2012).
2. Mao X, Ait-Aissa K, Lagrange J, Youcef G, Louis H. Hypertension, hypercoagulability and the metabolic syndrome: a cluster of risk factors for cardiovascular disease. Biomed. Mater. Eng. 22(1), 35-48 (2012).
3. Niiranen TJ, Thijs L, Asayama K et al. The International Database of Home blood pressure in relation to Cardiovascular Outcome (IDHOCO): moving from baseline characteristics to research perspectives. Hypertens. Res. 35(11), 1072-1079 (2012).
4. Georgiopoulou VV, Kalogeropoulos AP, Butler J. Heart failure in hypertension: prevention and treatment. Drugs 72(10), 1373-1398 (2012).
5. Kawai T, Ohishi M, Takeya Y et al. Serum uric acid is an independent risk factor for cardiovascular disease and mortality in hypertensive patients. Hypertens. Res. 35(11), 1087-1092 (2012).
6. Carvalho JJ, Baruzzi RG, Howard PF et al. Blood pressure in four remote populations in the INTERSALT Study. Hypertension 14, 238-246 (1989).
7. Guessous I, Bochud M, Theler JM, Gaspoz JM, Pechère-Bertschi A. 1999-2009 trends in prevalence, unawareness, treatment and control of hypertension in Geneva, Switzerland. PLoS One 7(6), e39877 (2012).
8. Gee ME, Bienek A, Campbell NR et al. Prevalence of, and barriers to, preventive lifestyle behaviors in hypertension (from a national survey of Canadians with hypertension). Am. J. Cardiol. 109(4), 570-575 (2012).
9. Madrigal L, Brady J, Raxter M, Ruiz E, Otarola F, Blell M. Obesity, hypertension, and migration: a meta-analysis of populations of the South Asian diaspora. Hum. Biol. 83(1), 71-86 (2011).
10. Blackburn H. 20th-century 'medical Marco Polos' in the origins of preventive cardiology and cardiovascular disease epidemiology. Am. J. Cardiol. 109(5), 756-767 (2012).
11. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275, 1571-1576 (1996).
12. Fujiyoshi A, Ohkubo T, Miura K et al. Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. Hypertens. Res. 35(9), 947-953 (2012).
13. Srivastava RK, Bachani D. Burden of NCDs, policies and programme for prevention and control of NCDs in India. Indian J. Community Med. 36(1), S7-S12 (2011).
14. Bhardwaj S, Misra A, Misra R et al. High prevalence of abdominal, intra-abdominal and subcutaneous adiposity and clustering of risk factors among urban Asian Indians in North India. PLoS One 6(9), e24362 (2011).
15. Kaplan NM, Victor RG. Primary hypertension-pathogenesis, natural history and evaluation. In: Kaplan's Clinical Hypertension (10th Edition). Lippincott-Williams & Wilkins Publications, PA, USA, 42-140 (2010).
16. Pal GK, Adithan C, Amudharaj D et al. Assessment of sympathovagal imbalance by spectral analysis of heart rate variability in prehypertensive and hypertensive patients in Indian population. Clin. Exp. Hypertens. 33(7), 478-483 (2011).
17. Pal GK, Shyma P, Habeebullah S, Shyjus P, Pal P, Nanda N. Association of albumin-globulin ratio with sympathovagal imbalance in pregnancy-induced hypertension. Indian J. Physiol. Pharmacol. 55(2), 128-138 (2011).
18. Pal GK, Shyma P, Habeebullah S, Pal P, Nanda N, Shyjus P. Vagal withdrawal and sympathetic overactivity contribute to the genesis of early-onset pregnancy-induced hypertension. Int. J. Hypertens. 2011, 361417 (2011).
19. Karthik S, Pal GK, Nanda N et al. Sympathovagal imbalance in thyroid dysfunctions in females: correlation with thyroid profile, heart rate and blood pressure. Indian J. Physiol. Pharmacol. 53(3), 243-252 (2009).
20. Shiina K, Tomiyama H, Takata Y et al. Effects of CPAP therapy on the sympathovagal balance and arterial stiffness in obstructive sleep apnea. Respir. Med. 104(6), 911-916 (2010).
21. Heemstra KA, Burggraaf J, van der Klaauw AA, Romijn JA, Smit JW, Corssmit EP. Short-term overt hypothyroidism induces sympathovagal imbalance in thyroidectomized differentiated thyroid carcinoma patients. Clin. Endocrinol. (Oxf. ) 72(3), 417-421 (2010).
22. Resmini E, Casu M, Patrone V et al. Sympathovagal imbalance in acromegalic patients. J. Clin. Endocrinol. Metab. 91(1), 115-120 (2006).
23. Piestrzeniewicz K, Łuczak K, Lelonek M, Wranicz JK, Goch JH. Obesity and heart rate variability in men with myocardial infarction. Cardiol. J. S15(1), 43-49 (2008).
24. Budeus M, Feindt P, Gams E et al. b-blocker prophylaxis for atrial fibrillation after coronary artery bypass grafting in patients with sympathovagal imbalance. Ann. Thorac. Surg. 84(1), 61-66 (2007).
25. Fujiki A, Nishida K, Mizumaki K, Nagasawa H, Shimono M, Inoue H. Spontaneous onset of torsade de pointes in long-QT syndrome and the role of sympathovagal imbalance. Jpn. Circ. J. 65(12), 1087-1090 (2001).
26. Pozzati A, Pancaldi LG, Di Pasquale G, Pinelli G, Bugiardini R. Transient sympathovagal imbalance triggers 'ischemic' sudden death in patients undergoing electrocardiographic Holter monitoring. J. Am. Coll. Cardiol. 27(4), 847-852 (1996).
27. Tseng CD, Wang TL, Lin JL et al. The mechanism of sympathovagal imbalance in patients with myocardial ischemia. Jpn. Heart J. 37(1), 43-58 (1996).
28. Toikka JO, Laine H, Ahotupa M et al. Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension 36(6), 929-933 (2000).
29. Cuspidi C, Negri F, Sala C, Mancia G. Masked hypertension and echocardiographic left ventricular hypertrophy: an updated overview. Blood Press. Monit. 17(1), 8-13 (2012).
30. Kim SH, Cho GY, Baik I et al. Early abnormalities of cardiovascular structure and function in middle-aged Korean adults with prehypertension: the Korean Genome Epidemiology study. Am. J. Hypertens. 24(2), 218-224 (2011).
31. Kotchen TA. Pathologic consequences of hypertension. In: Harrison's Principles of Internal Medicine (17th Edition). Fauci AS, Kasper DL, Longo DL et al (Eds). McGraw Hill Publications, NY, USA, 1552-1553 (2008).
32. Cuspidi C, Vaccarella A, Negri F, Sala C. Resistant hypertension and left ventricular hypertrophy: an overview. J. Am. Soc. Hypertens. 4(6), 319-324 (2010).
33. Thomas-Kvidera D. Heart failure from diastolic dysfunction related to hypertension: guidelines for management. J. Am. Acad. Nurse Pract. 17(5), 168-175 (2005).
34. Arima H, Murakami Y, Lam TH et al. Asia Pacific Cohort Studies Collaboration. Effects of prehypertension and hypertension subtype on cardiovascular disease in the Asia-Pacific Region. Hypertension 59(6), 1118-1123 (2012).
35. Giannarelli C, Bianchini E, Bruno RM et al. Local carotid stiffness and intima-media thickness assessment by a novel ultrasound-based system in essential hypertension. Atherosclerosis 223(2), 372-377 (2012).
36. Kalra SS, Shanahan CM. Vascular calcification and hypertension: cause and effect. Ann. Med. 44, S85-S92 (2012).
37. Jeemon P, Prabhakaran D, Goenka S et al. Impact of comprehensive cardiovascular risk reduction programme on risk factor clustering associated with elevated blood pressure in an Indian industrial population. Indian J. Med. Res. 135(4), 485-493 (2012).
38. Greathouse MK, Weir MR. The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications. Postgrad. Med. 124(2), 40-52 (2012).
39. Pal GK. Sympathetic and parasympathetic systems. In: Textbook of Medical Physiology. Ahuja Publications, New Delhi, India, 209-216 (2010).
40. Pal GK. Role of sympathovagal balance in achieving effective homeostasis. Biomedicine 28(2), 67-68 (2008).
41. Pal GK, Pal P. Spectral analysis of heart rate variability. In: Textbook of Practical Physiology (3rd Edition). Universities Press, Hyderabad, India (2010).
42. Mathias CJ, Bannister R. Investigation of autonomic disorders. In: Autonomic Failure: a Textbook of Clinical Disorders of Autonomic Nervous System (3rd Edition). Bannister RS, Mathias CJ (Eds). Oxford University Press, Oxford, UK, 255-290 (1992).
43. Martens A, Greenberg J, Allen JJ. Self-esteem and autonomic physiology: parallels between self-esteem and cardiac vagal tone as buffers of threat. Pers. Soc. Psychol. Rev. 12(4), 370-389 (2008).
44. Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int. J. Cardiol. 141, 122-131 (2010).
45. Pagani M, Lombardi F, Guzzetti S et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympathovagal interaction in man and conscious dog. Circ. Res. 59, 178-193 (1986).
46. Malliani A. Heart rate variability: from bench to bedside. Eur. J. Int. Med. 16, 12-60 (2005).
47. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Emotions, morbidity, and mortality: new perspectives from psychoneuroimmunology. Annu. Rev. Psychol. 53, 83-107 (2002).
48. Heart rate variability. Standard and measurement, physiological interpretation and clinical use. Task force of the European Society of Cardiology and the North American society of Pacing and Electrophysiology. Circulation 93, 1043-1065 (1996).
49. Tsuji H, Venditti FJ Jr, Manders ES et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 90, 878-883 (1994).
50. Gerritsen J, Dekker JM, TenVoorde BJ et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care 24, 1793-1798 (2001).
51. Liao D, Carnethon M, Evans GW, Cascio WE, Heiss G. Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: the atherosclerosis risk in communities (ARIC) study. Diabetes 51, 3524-3531 (2002).
52. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (autonomic tone and reflexes after myocardial infarction) investigators. Lancet 351, 478-484 (1998).
53. Camm AJ, Pratt CM, Schwartz PJ et al. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 109, 990-996 (2004).
54. Eckberg DL. Sympathovagal balance: a critical appraisal. Circulation 96, 3224-3232 (1997).
55. Houle MS, Billman GE. Low-frequency component of the heart rate variability spectrum: a poor marker of sympathetic activity. Am. J. Physiol. 276, H215-H223 (1999).
56. Madden K, Savard GK. Effects of mental state on heart rate and blood pressure variability in men and women. Clin. Physiol. 15, 557-569 (1995).
57. Gabor A, Leenen FH. Central neuromodulatory pathways regulating sympathetic activity in hypertension. J. Appl. Physiol. 113(8), 1294-1303 (2012).
58. Hogarth AJ, Graham LN, Corrigan JH, Deuchars J, Mary DA, Greenwood JP. Sympathetic nerve hyperactivity and its effect in postmenopausal women. J. Hypertens. 29, 2167-2175 (2011).
59. Benjelloun H, Aboudrar S, Jroundi I, Benjelloun-Bennani H, Coghlan L, Benomar M. Sympathetic response in primary hypertension. Ann. Cardiol. Angeiol. (Paris) 58, 139-143 (2009).
60. Hogarth AJ, Burns J, Mackintosh AF, Mary DA. Sympathetic nerve hyperactivity of essential hypertension is lower in postmenopausal women than men. J. Hum. Hypertens. 22, 544-549 (2008).
61. Hogarth AJ, Mackintosh AF, Mary DA. The effect of gender on the sympathetic nerve hyperactivity of essential hypertension. J. Hum. Hypertens. 21, 239-245 (2007).
62. Amerena J, Julius S. Role of the autonomic nervous system in hypertension. Hypertens. Res. 18, 99-110 (1995).
63. Julius S, Krause L, Schork N et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J. Hypertens. 9, 77-84 (1991).
64. Pickering GW. The peripheral resistance in persistent arterial hypertension. Clin. Sci. 2, 209 (1936).
65. Kawano Y, Fukiyama K, Takeya T, Abe I, Omae T. Elevated plasma catecholamines without alteration in cardiovascular responsiveness in young men with borderline hypertension. Am. Heart J. 104, 1351-1356 (1982).
66. Aoi W, Kuramochi M, Hashiba K. Neurohumoral factors in borderline hypertension. Jpn. Circ. J. 47, 258-267 (1983).
67. Kawano Y, Fukiyama K, Takeya Y, Abe I, Kawasaki T, Omae T. Augmented sympathetic nervous function in young subjects with borderline hypertension. Jpn. Circ. J. 46, 483-485 (1982).
68. Folkow B. Physiological aspects of primary hypertension. Physiol. Rev. 62, 347-503 (1982).
69. Conway J. A vascular abnormality in hypertension: a study of blood flow in the forearm. Circulation 27, 520-529 (1963).
70. Sivertsson R. The hemodynamic importance of structural vascular changes in essential hypertension. Acta Physiol. Scand. 79, 3-56 (1970).
71. Egan B, Panis R, Hinderliter A, Schork N, Julius S. Mechanism of increased a-adrenergic vasoconstriction in human essential hypertension. J. Clin. Invest. 80, 812-817 (1987).
72. Dinenno FA, Jones PP, Seals DR, Tanaka H. Age-associated arterial wall thickening is related to elevations in sympathetic activity in healthy humans. Am. J. Physiol. Heart Circ. Physiol. 278, H1205-H1210 (2000).
73. Joannides R, Richard V, Moore N, Godin M, Thuillez C. Influence of sympathetic tone on mechanical properties of muscular arteries in humans. Am. J. Physiol. 268, H794-H801 (1995).
74. Mazzone SB, Lim LH, Wagner EM, Mori N, Canning BJ. Sympathetic nerve-dependent regulation of mucosal vascular tone modifies airway smooth muscle reactivity. J. Appl. Physiol. 109, 1292-1300 (2010).
75. Xu H, Fink GD, Galligan JJ. Increased sympathetic venoconstriction and reactivity to norepinephrine in mesenteric veins in anesthetized DOCA-salt hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 293, H160-H168 (2007).
76. Liao D, Cai J, Barnes RW et al. Association of cardiac autonomic function and the development of hypertension: the ARIC study. Am. J. Hypertens. 9, 1147-1156 (1996).
77. Singh JP, Larson MG, Tsuji H, Evans JC, O'Donnell CJ, Levy D. Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study. Hypertension 32, 293-297 (1998).
78. Schroeder EB, Liao D, Chambless LE, Prineas RJ, Evans GW, Heiss G. Hypertension, blood pressure, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Hypertension 42, 1106-1111 (2003).
79. Palatini P. Elevated heart rate as a predictor of increased cardiovascular morbidity. J. Hypertens. Suppl. 17, S3-S10 (1999).
80. Masi CM, Hawkley LC, Rickett EM, Cacioppo JT. Respiratory sinus arrhythmia and diseases of aging: obesity, diabetes mellitus, and hypertension. Biol. Psychol. 74, 212-223 (2007).
81. Dabrowska B, Dabrowski A, Skrobowski A. Parasympathetic withdrawal precedes spontaneous blood pressure elevations in women with primary hypertension. Cardiology 87, 119-124 (1996).
82. Barrett KE, Barman SM, Biotano S, Brooks HA. Cardiovascular regulatory mechanisms. In: Ganong's Review of Medical Physiology (23rd Edition). McGraw Hill-Lange Publications, NY, USA, 555-568 (2010).
83. Manabe H, Fukuma N, Tuchida T, Kato Y, Mabuchi K, Takano T. Analysis of alteration of blood pressure response to exercise through baroreflex. J. Nippon. Med. Sch. 74, 123-130 (2007).
84. Pal GK. Blood pressure and its regulation. In: Textbook of Medical Physiology. Ahuja Publications, New Delhi, India, 209-216 (2010).
85. Taylor AA. Autonomic control of cardiovascular function: clinical evaluation in health and disease. J. Clin. Pharmacol. 34, 363-374 (1994).
86. Schreihofer AM, Ito S, Sved AF. Brain stem control of arterial pressure in chronic arterial baroreceptor-denervated rats. Am. J. Physiol. 289, R1746-R1755 (2005).
87. Mancia G, Grassi G, Parati G et al. Control of circulation by arterial baroreceptors and cardiopulmonary receptors in hypertension. J. Cardiovasc. Pharmacol. 8, S82-S88 (1986).
88. Heesch CM, Crandall ME, Turbek JA. Converting enzyme inhibitors cause pressureindependent resetting of baroreflex control of sympathetic outflow. Am. J. Physiol. 270, R728-R737 (1996).
89. Takahashi H, Yoshika M, Komiyama Y, Nishimura M. The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain. Hypertens. Res. 34, 1147-1160 (2011).
90. Huang BS, White RA, Ahmad M, Jeng AY, Leenen FH. Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats. Am. J. Physiol. 295, R166-R172 (2008).
91. Zhang ZH, Yu Y, Kang YM, Wei SG, Felder RB. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am. J. Physiol. 294, H1067-H1074 (2008).
92. Huang BS, Leenen FH. Brain 'ouabain' mediates the sympathoexcitatory and hypertensive effects of high sodium intake in Dahl salt-sensitive rats. Circ. Res. 74, 586-595 (1994).
93. Houghton BL, Huang C, Johns EJ. Influence of dietary sodium on the blood pressure and renal sympathetic nerve activity responses to intracerebroventricular angiotensin II and angiotensin III in anaesthetized rats. Exp. Physiol. 95, 282-295 (2010).
94. Zimmerman MC, Lazartigues E, Lang JA et al. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ. Res. 91, 1038-1045 (2002).
95. Schechter PJ, Horwitz D, Henkin RI. Sodium chloride preference in essential hypertension. JAMA 225, 1311-1315 (1973).
96. Schechter PJ, Horwitz D, Henkin RI. Salt preference in patients with untreated and treated essential hypertension. Am. J. Med. Sci. 267, 320-326 (1974).
97. Contreras RJ. Salt taste and disease. Am. J. Clin. Nutr. 31, 1088-1097 (1978).
98. Ben-Ishay D, Dikstein S, Shalita B. Sodium chloride preference in hypertensive (H) and normotensive (N) rats. Pflugers Arch. 361, 153-157 (1976).
99. Di Nicolantonio R, Mendelsohn FA, Hutchinson JS. Sodium chloride preference of genetically hypertensive and normotensive rats. Am. J. Physiol. 245, R38-R44 (1983).
100. Ferrell F, Gray SD. Longitudinal study of salt preferences in normotensive and hypertensive rats. Hypertension 7, 326-332 (1985).
101. Barnwell GM, Dollahite J, Mitchell DS. Salt taste preference in baboons. Physiol. Behav. 37, 279-284 (1986).
102. Di Nicolantonio R, Silvapulle MJ. Blood pressure, salt appetite and mortality of genetically hypertensive and normotensive rats maintained on high and low salt diets from weaning. Clin. Exp. Pharmacol. Physiol. 15, 741-751 (1988).
103. Mattes RD. Salt taste and hypertension: a critical review of the literature. J. Chronic Dis. 37, 195-208 (1984).
104. Ando K, Fujita M. Reactive oxygen species and the central nervous system in salt-sensitive hypertension: possible relationship with obesity-induced hypertension. Clin. Exp. Pharmacol. Physiol. 39, 111-116 (2012).
105. Babkin AP, Gladkikh VV, Pershukov IV. Salt sensitivity in patients with arterial hypertension. Kardiologiia 50, 57-62 (2010).
106. Yatabe MS, Yatabe J, Yoneda M et al. Salt sensitivity is associated with insulin resistance, sympathetic overactivity, and decreased suppression of circulating renin activity in lean patients with essential hypertension. Am. J. Clin. Nutr. 92, 77-82 (2010).
107. Hori Y, Toyoshima H, Kondo T et al. Gender and age differences in lifestyle factors related to hypertension in middle-aged civil service employees. J. Epidemiol. 13, 38-47 (2003).
108. Hamlyn JM, Levinson PD, Ringel R et al. Relationships among endogenous digitalis-like factors in essential hypertension. Fed. Proc. 44, 2782-2788 (1985).
109. Cloix JF, Devynck MA, Meyer P. Chemical and clinical studies of endogenous digitalis like factor in hypertension. Ann. N. Y. Acad. Sci. 488, 217-227 (1986).
110. Kelly RA, O'Hara DS, Mitch WE et al. Endogenous digitalis-like factors in hypertension and chronic renal insufficiency. Kidney Int. 30, 723-739 (1986).
111. Graves SW, Williams GH. Endogenous digitalis-like natriuretic factors. Annu. Rev. Med. 38, 433-444 (1987).
112. Tymiak AA, Norman JA, Bolgar M et al. Physicochemical characterization of a ouabain isomer isolated from bovine hypothalamus. Proc. Natl Acad. Sci. USA 90, 8189-8193 (1993).
113. Sancho JM. A non-ouabain Na/K ATPase inhibitor isolated from bovine hypothalamus. Its relation to hypothalamic ouabain. Clin. Exp. Hypertens. 20, 535-542 (1998).
114. Campos RR, Bergamaschi CT. Neurotransmission alterations in central cardiovascular control in experimental hypertension. Curr. Hypertens. Rev. 2, 193-198 (2006).
115. Hirooka Y, Kishi T, Sakai K, Takeshita A, Sunagawa K. Imbalance of central nitric oxide and reactive oxygen species in the regulation of sympathetic activity and neural mechanisms of hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300, R818-R826 (2011).
116. Lin LH. Glutamatergic neurons say NO in the nucleus tractus solitarii. J. Chem. Neuroanat. 38, 1154-1165 (2009).
117. Patel KP, Li YF, Hirooka Y. Role of nitric oxide in central sympathetic outflow. Exp. Biol. Med. (Maywood) 226, 814-824 (2001).
118. Zanzinger J. Role of nitric oxide in the neural control of cardiovascular function. Cardiovasc. Res. 43, 639-649 (1999).
119. Eshima K, Hirooka Y, Shigematsu H et al. Angiotensin in the nucleus tractus solitarii contributes to neurogenic hypertension caused by chronic nitric oxide synthase inhibition. Hypertension 36, 259-263 (2000).
120. Sander M, Chavoshan B, Victor RG. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension 33, 937-942 (1999).
121. Briones AM, Touyz RM. Oxidative stress and hypertension: current concepts. Curr. Hypertens. Rep. 12, 135-142 (2010).
122. Hirooka Y. Role of reactive oxygen species in brainstem in neural mechanisms of hypertension. Auton. Neurosci. 142, 20-24 (2008).
123. Hirooka Y, Sagara Y, Kishi T, Sunagawa K. Oxidative stress and central cardiovascular regulation: pathogenesis of hypertension and therapeutic aspects. Circ. J. 74, 827-835 (2010).
124. Kishi T, Hirooka Y, Kimura Y, Ito K, Shimokawa H, Takeshita A. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 109, 2357-2362 (2004).
125. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ. Res. 95, 210-216 (2004).
126. Chan SHH, Tai MH, Li CY, Chan JYH. Reduction in molecular synthesis or enzyme activity of superoxide dismutase and catalase contributes to oxidative stress and neurogenic hypertension in spontaneously hypertensive rats. Free Radic. Biol. Med. 40, 2028-2039 (2006).
127. Ren J. Influence of gender on oxidative stress, lipid peroxidation, protein damage and apoptosis in hearts and brains from spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 34, 432-438 (2007).
128. Török J. Participation of nitric oxide in different models of experimental hypertension. Physiol. Res. 57, 813-825 (2008).
129. Lincoln J, Burnstock G. Neural-endothelial interactions in control of local blood flow. In: The Endothelium: an Introduction to Current Research. Warren J (Ed. ). Wiley-Liss, NY, USA, 21-31 (1990).
130. Kuneš J, Hojná S, Kadlecová M et al. Altered balance of vasoactive systems in experimental hypertension: the role of relative NO deficiency. Physiol. Res. 53(Suppl. 1), S23-S34 (2004).
131. Kishi T, Hirooka Y, Konno S, Sunagawa K. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. J. Hypertens. 30, 1646-1655 (2012).
132. Ettner R, Ettner F, White T. Secrecy and the pathogenesis of hypertension. Int. J. Family Med. 2012, 492718 (2012).
133. Yan LL, Liu K, Matthews KA, Daviglus ML, Ferguson TF, Kiefe CI. Psychosocial factors and risk of hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. JAMA 290, 2138-2148 (2003).
134. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom. Med. 66, 802-813 (2004).
135. Ward HE. Depression and cardiovascular disease. Curr. Opin. Psychiatry 16, 221-225 (2003).
136. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937-952 (2004).
137. Macleod J, Davey Smith G, Heslop P, Metcalfe C, Carroll D, Hart C. Psychological stress and cardiovascular disease: empirical demonstration of bias in a prospective observational study of Scottish men. BMJ 324, 1247-1251 (2002).
138. Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J. Psychosom. Res. 53, 897-902 (2002).
139. Sheps DS, Sheffield D. Depression, anxiety, and the cardiovascular system: the cardiologist's perspective. J. Clin. Psychiatry 62(8), 12-16 (2001).
140. Kang MG, Koh SB, Cha BS, Park JK, Woo JM, Chang SJ. Association between job stress on heart rate variability and metabolic syndrome in shipyard male workers. Yonsei Med. J. 45, 838-846 (2004).
141. Chandola T, Britton A, Brunner E et al. Work stress and coronary heart disease: what are the mechanisms? Eur. Heart J. 29, 640-648 (2008).
142. Riese H, Van Doornen LJ, Houtman IL, De Geus EJ. Job strain in relation to ambulatory blood pressure, heart rate, and heart rate variability among female nurses. Scand. J. Work Environ. Health 30, 477-485 (2004).
143. Milutinovi D, Golubovi B, Brki N, Prokeš B. Professional stress and health among critical care nurses in Serbia. Arh. Hig. Rada Toksikol. 63(2), 171-180 (2012).
144. Kaur M. Blood pressure trends and hypertension among rural and urban Jat women of Haryana, India. Coll. Antropol. 36(1), 139-144 (2012).
145. Rosenthal T, Alter A. Occupational stress and hypertension. J. Am. Soc. Hypertens. 6(1), 2-22 (2012).
146. Trudel X, Brisson C, Milot A. Job strain and masked hypertension. Psychosom. Med. 72(8), 786-793 (2010).
147. Alves MG, Chor D, Faerstein E, Werneck GL, Lopes CS. Job strain and hypertension in women: Estudo Pro-Saúde (Pro-Health Study). Rev. Saude Publica. 43(5), 893-896 (2009).
148. Wong IS, Ostry AS, Demers PA, Davies HW. Job strain and shift work influences on biomarkers and subclinical heart disease indicators: a pilot study. J. Occup. Environ. Hyg. 9(8), 467-477 (2012).
149. Worrall-Carter L, Ski C, Scruth E, Campbell M, Page K. Systematic review of cardiovascular disease in women: assessing the risk. Nurs. Health Sci. 13(4), 529-535 (2011).
150. Padwal RJ, Hemmelgarn BR, Khan NA et al. Canadian Hypertension Education Program. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1-blood pressure measurement, diagnosis and assessment of risk. Can. J. Cardiol. 24(6), 455-463 (2008).
151. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 9(2), 117-123 (2008).
152. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 92(12), 1752-1759 (2006).
153. de Winter CF, Bastiaanse LP, Hilgenkamp TI, Evenhuis HM, Echteld MA. Cardiovascular risk factors (diabetes, hypertension, hypercholesterolemia and metabolic syndrome) in older people with intellectual disability: results of the HA-ID study. Res. Dev. Disabil. 33(6), 1722-1731 (2012).
154. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N. Engl. J. Med. 317, 350-357 (1987).
155. Williams RR, Hunt SC, Hopkins PN et al. Familial dyslipidemic hypertension. JAMA 259, 3579-3586 (1988).
156. Kaplan NM. The deadly quartet. Upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch. Intern. Med. 149, 1514-1520 (1989).
157. Shimomura T, Wakabayashi I. Associations of cardiovascular risk factors with prehypertension and hypertension in women. Blood Press doi:10. 3109/08037051. 2012. 6861 (2012) (Epub ahead of print).
158. Chin D, Battistoni A, Tocci G, Passerini J, Parati G, Volpe M. Non-invasive diagnostic testing for coronary artery disease in the hypertensive patient: potential advantages of a risk estimation-based algorithm. Am. J. Hypertens. 25(12), 1226-1235 (2012).
159. Lovallo WR. Cardiovascular reactivity: mechanisms and pathways to cardiovascular disease. Int. J. Psychophysiol. 58, 119-132 (2005).
160. Raheja P, Price A, Wang Z et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension 60(2), 319-325 (2012).
161. Smith MM, Minson CT. Obesity and adipokines: effects on sympathetic overactivity. J. Physiol. 590(8), 1787-1801 (2012).
162. De Angelis K, Senador DD, Mostarda C, Irigoyen MC, Morris M. Sympathetic overactivity precedes metabolic dysfunction in a fructose model of glucose intolerance in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302(8), R950-R957 (2012).
163. Mangos GJ, Spaan JJ, Pirabhahar S, Brown MA. Markers of cardiovascular disease risk after hypertension in pregnancy. J. Hypertens. 30(2), 351-358 (2012).
164. Gomes ME, El Messaoudi S, Lenders JW et al. High dose ascorbic acid does not reverse central sympathetic overactivity in chronic heart failure. J. Clin. Pharm. Ther. 36(5), 546-552 (2011).
165. Zoccal DB, Machado BH. Sympathetic overactivity coupled with active expiration in rats submitted to chronic intermittent hypoxia. Respir. Physiol. Neurobiol. 174(1-2), 98-101 (2010).
166. Perkes I, Baguley IJ, Nott MT, Menon DK. A review of paroxysmal sympathetic hyperactivity after acquired brain injury. Ann. Neurol. 68(2), 126-135 (2010).
167. Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol. Rev. 90(2), 513-557 (2010).
168. Zhao M, Sun L, Liu JJ, Wang H, Miao Y, Zang WJ. Vagal nerve modulation: a promising new therapeutic approach for cardiovascular diseases. Clin. Exp. Pharmacol. Physiol. 39(8), 701-705 (2011).
169. Calvillo L, Vanoli E, Andreoli E et al. Vagal stimulation, through its nicotinic action, limits infarct size and the inflammatory response to myocardial ischemia and reperfusion. J. Cardiovasc. Pharmacol. 58(5), 500-507 (2011).
170. Schwartz PJ. Vagal stimulation for heart diseases: from animals to men-an example of translational cardiology. Circ. J. 75(1), 20-27 (2011).
171. Schwartz PJ, De Ferrari GM. Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail. Rev. 16(2), 101-107 (2011).
172. Zang WJ, Sun L, Yu XJ, Lv J, Chen LN, Liu BH. Vagal control of cardiac functions and vagal protection of ischemic myocardium. Sheng Li Xue Bao 60(4), 443-452 (2008).
173. Pal GK, Pal P, Nanda N, Amudharaj D, Karthik S. Spectral analysis of heart rate variability (HRV) may predict the future development of essential hypertension. Med. Hypotheses 72(2), 183-185 (2009).
174. Ogunleye OO, Ogundele SO, Akinyemi JO, Ogbera AO. Clustering of hypertension, diabetes mellitus and dyslipidemia in a nigerian population: a cross sectional study. Afr. J. Med. Med. Sci. 41(2), 191-195 (2012).
175. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003).
176. Pankova NB, Alchinova IB, Afanas'eva EV, Karganov MIu. Functional characteristics of cardiovascular system in adolescents with prehypertension. Fiziol. Cheloveka 36(3), 82-89 (2010).
177. Drukteinis JS, Roman MJ, Fabsitz RR et al. Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: the Strong Heart Study. Circulation 115(2), 221-227 (2007).
178. Tirosh A, Afek A, Rudich A et al. Progression of normotensive adolescents to hypertensive adults: a study of 26, 980 teenagers. Hypertension 56(2), 203-209 (2010).
179. Natali A, Muscelli E, Casolaro A et al. Metabolic characteristics of prehypertension: role of classification criteria and gender. J. Hypertens. 27(12), 2394-2402 (2009).
180. Greenlund KJ, Daviglus ML, Croft JB. Differences in healthy lifestyle characteristics between adults with prehypertension and normal blood pressure. J. Hypertens. 27(5), 955-962 (2009).
181. Ishikawa Y, Ishikawa J, Ishikawa S, Kayaba K. Jichi Medical School Cohort Investigators Group. Prevalence and determinants of prehypertension in a Japanese general population: the Jichi Medical School Cohort Study. Hypertens. Res. 31(7), 1323-1330 (2008).
182. Singh RB, Fedacko J, Pella D, Five City Study Group, Gupta AK. Prevalence and risk factors for prehypertension and hypertension in five Indian cities. Acta Cardiol. 66(1), 29-37 (2011).
183. Pal GK, Chandrasekaran A, Hariharan AP et al. Body mass index contributes to sympathovagal imbalance in prehypertensives. BMC Cardiovasc. Disord. 12(1), 54 (2012).
184. Pal GK, Pal P, Lalitha V et al. Increased vascular tone due to sympathovagal imbalance in normotensive and prehypertensive offspring of hypertensive parents. Int. Angiol. 31(4), 340-347 (2012).
185. Pal GK, Amudharaj D, Pal P et al. Study of sympathovagal imbalance by spectral analysis of heart rate variability in young prehypertensives. Ind. J. Physiol. Pharmacol. 55(4), 357-363 (2011).
186. Pal GK, Pal P, Nanda N, Lalitha V, Dutta TK, Adithan C. Sympathovagal imbalance in young prehypertensives: importance of male-female difference. Am. J. Med. Sci. doi:10. 1097/MAJ. 0b013e31824ba080 (2012) (Epub ahead of print).
187. Pal GK, Pal P, Nanda N, Lalitha V, Dutta TK, Adithan C. Effect of gender on sympathovagal imbalance in prehypertensives. Clin. Exp. Hypertens. 34(1), 31-37 (2012).
188. Pal GK, Pal P, Nanda N, Lalitha V, Dutta TK, Adithan C. Sympathovagal imbalance in prehypertensive offspring of two parents versus one parent hypertensive. Int. J. Hypertens. 2011, 263170 (2011).
189. Konnov MV, Dobordzhginidze LM, Deev AD, Gratsianski NA. Own and parental predictors of arterial prehypertension and hypertension in children of persons with premature coronary heart disease. Kardiologiia 50(3), 22-25 (2010).
190. Gedikli O, Kiris A, Ozturk S et al. Effects of prehypertension on arterial stiffness and wave reflections. Clin. Exp. Hypertens. 32(2), 84-89 (2010).
191. Zhu H, Yan W, Ge D et al. Cardiovascular characteristics in American youth with prehypertension. Am. J. Hypertens. 20(10), 1051-1057 (2007).
192. Li C, Li Y, Wang X, Zhang S, Ning G, Zheng X. Cardiac dysfunction investigation in prehypertension. Eng. Med. Biol. Soc. 7, 7628-7631 (2005).
193. Collier SR, Landram MJ. Treatment of prehypertension: lifestyle and/or medication. Vasc. Health. Risk. Manag. 8, 613-619 (2012).
194. Urbina EM, Khoury PR, McCoy C, Daniels SR, Kimball TR, Dolan LM. Cardiac and vascular consequences of pre-hypertension in youth. J. Clin. Hypertens. (Greenwich) 13(5), 332-342 (2011).
195. Pal GK. Association of cardiovascular risks with sympathovagal imbalance in rheumatoid arthritis. Indian J. Med. Res. 136(4), 547-548 (2012).
196. Erdogan D, Gonul E, Icli A et al. Effects of normal blood pressure, prehypertension, and hypertension on autonomic nervous system function. Int. J. Cardiol. 151(1), 50-53 (2011).
197. Rosenwinkel ET, Bloomfield DM, Arwady MA, Goldsmith RL. Exercise and autonomic function in health and cardiovascular disease. Cardiol. Clin. 19, 369-387 (2001).
198. Cooke WH, Reynolds BV, Yandl MG, Carter JR, Tahvanainen KU, Kuusela TA. Effects of exercise training on cardiovagal and sympathetic responses to Valsalva's maneuver. Med. Sci. Sports Exerc. 34, 928-935 (2002).
199. Cornelissen VA, Verheyden B, Aubert AE, Fagard RH. Effects of aerobic training intensity on resting, exercise and post-exercise blood pressure, heart rate and heart-rate variability. J. Hum. Hypertens. 24, 175-182 (2010).
200. Bond V, Bartels MN, Sloan RP et al. Exercise training favourably affects autonomic and blood pressure responses during mental and physical stressors in African-American men. J. Hum. Hypertens. 23, 267-273 (2009).
201. Collier SR, Kanaley JA, Carhart R Jr et al. Cardiac autonomic function and baroreflex changes following 4 weeks of resistance versus aerobic training in individuals with pre-hypertension. Acta Physiol. (Oxf. ). 195, 339-348 (2009).
202. Mos L, Driussi C, Mihaleje M. Hypertension and sports activity. G. Ital. Cardiol. (Rome) 11, S98-S101 (2010).
203. Martins-Pinge MC. Cardiovascular and autonomic modulation by the central nervous system after aerobic exercise training. Braz. J. Med. Biol. Res. 44, 848-854 (2011).
204. de Jonge L, Moreira EA, Martin CK, Ravussin E. Pennington CALERIE Team. Impact of 6-month caloric restriction on autonomic nervous system activity in healthy, overweight, individuals. Obesity (Silver Spring) 18(2), 414-416 (2010).
205. Emdin M, Gastaldelli A, Muscelli E et al. Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. Circulation 103(4), 513-519 (2001).
206. Anand MP. Non-pharmacological management of essential hypertension. J. Ind. Med. Assoc. 97(6), 220-225 (1999).
207. Jayasinghe SR. Yoga in cardiac health. Eur. J. Cardiovasc. Prev. Rehabil. 11(5), 369-375 (2004).
208. Kristal AR, Littman AJ, Benitez D, White E. Yoga practice is associated with attenuated weight gain in healthy, middle-aged men and women. Altern. Ther. Health Med. 11(4), 28-33 (2005).
209. Wang SZ, Li S, Xu XY et al. Effect of slow abdominal breathing combined with biofeedback on blood pressure and heart rate variability in prehypertension. J. Altern. Complement Med. 16, 1039-1045 (2010).
210. Pal GK, Velkumary S, Madanmohan. Effects of slow and fast breathing exercises on autonomic functions in young student volunteers. Ind. J. Med. Res. 3, 154-160 (2004).
211. Ducla-Soares JL, Santos-Bento M, Laranjo S et al. Wavelet analysis of autonomic outflow of normal subjects on head-up tilt, cold pressor test, Valsalva maneuver and deep breathing. Exp. Physiol. 92, 677-686 (2007).
212. Pramanik T, Sharma HO, Mishra S et al. Immediate effect of slow pace bhastrika pranayama on blood pressure and heart rate. J. Altern. Complement Med. 15, 293-295 (2009).
213. Mozaffarian D, Stein PK, Prineas RJ, Siscovick DS. Dietary fish and w-3 fatty acid consumption and heart rate variability in US adults. Circulation 117, 1130-1137 (2008).
214. Park SK, Tucker KL, O'Neill MS et al. Fruit, vegetable, and fish consumption and heart rate variability: the Veterans Administration Normative Aging Study. Am. J. Clin. Nutr. 89, 778-786 (2009).
215. Bertisch SM, Schomer A, Kelly EE et al. Device-guided paced respiration as an adjunctive therapy for hypertension in obstructive sleep apnea: a pilot feasibility study. Appl. Psychophysiol. Biofeedback 36, 173-179 (2011).
216. Sica DA. Device-guided breathing and hypertension: a yet to be determined positioning. Cardiol. Rev. 19, 45-46 (2011).
217. Sharma M, Frishman WH, Gandhi K. RESPeRATE: nonpharmacological treatment of hypertension. Cardiol. Rev. 19, 47-51 (2011).